SCHEMBL12010352

SCHEMBL12010352

CCCN(C)S(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.56
ALDH1A1 P00352 2/20 0.42
BDKRB1 P46663 1/20 0.41
TSHR P16473 2/20 0.41
HSD11B1 P28845 1/20 0.40
ESR1 P03372 5/20 0.40
KMT2A Q03164 2/20 0.38
LMNA P02545 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.37
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CCR4 P51679 1/20 0.36
AKR1B1 P15121 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7847967 0.87 MCOLN3 (0.56) MCOLN3ALDH1A1BDKRB1TSHRHSD11B1
SCHEMBL12077622 0.87 PGR (0.47) MCOLN3ALDH1A1HSD11B1ESR1KMT2A
SCHEMBL4033271 0.86 MCOLN3 (0.55) MCOLN3ALDH1A1BDKRB1TSHRHSD11B1
SCHEMBL10455037 0.85 MCOLN3 (0.54) MCOLN3ALDH1A1TSHRHSD11B1ESR1
SCHEMBL15314381 0.83 MCOLN3 (0.52) MCOLN3ALDH1A1BDKRB1TSHRHSD11B1
SCHEMBL5383623 0.83 MCOLN3 (0.52) MCOLN3ALDH1A1BDKRB1TSHRHSD11B1
SCHEMBL3439979 0.82 MCOLN3 (0.55) MCOLN3ALDH1A1BDKRB1HSD11B1KMT2A
SCHEMBL5111158 0.80 MCOLN3 (0.52) MCOLN3ALDH1A1BDKRB1HSD11B1KMT2A
SCHEMBL12010353 0.80 MCOLN3 (0.49) MCOLN3ALDH1A1BDKRB1TSHRHSD11B1
SCHEMBL11812003 0.80 TDP1 (0.53) ALDH1A1TSHRKMT2AMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450306-B2 Bradykinin B1-receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8252785-B2 Aryl sulfonamides as bradykinin-B1-receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-28 US disclosed
US-20110294775-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 US disclosed
US-20110021488-A1 New Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021488-A1 New Compounds ABCG2, ADORA2B, ADORA3 MCOLN3 2334/4885ALDH1A1 428/4885BDKRB1 7/4885
US-20110294775-A1 NOVEL COMPOUNDS TRPV1, OPRL1, TRPA1 MCOLN3 1457/4885ALDH1A1 2740/4885BDKRB1 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.